Biotechnology company 10x Genomics and Harvard University reached a Feb. 6 settlement in a patent lawsuit that they jointly ...
At the Advances in Genome Biology and Technology, AGBT, General Meeting, 10x Genomics (TXG) announced a series of new product innovations to ...
A Wednesday night earnings report left big questions about how the spending reductions would affect the company.
General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, announced a series of new ...
Hosted on MSN14d
10x Genomics (NASDAQ:TXG) Exceeds Q4 Expectations But Full-Year Sales Guidance Misses ExpectationsBiotech company 10x Genomics (NASDAQ:TXG) reported Q4 CY2024 results , but sales fell by 10.3% year on year to $165 million. On the other hand, the company’s full-year revenue guidance of $620 million ...
Leerink Partnrs downgraded shares of 10x Genomics (NASDAQ:TXG – Free Report) from a strong-buy rating to a hold rating in a ...
Allspring Global Investments Holdings LLC decreased its holdings in 10x Genomics, Inc. (NASDAQ:TXG – Free Report) by 25.0% during the fourth quarter, according to its most recent filing with the ...
10X Genomics, Inc. is a life science technology company, which engages in building products to interrogate, understand and master biology. Its integrated solutions include single cell ...
TD Cowen analyst Dan Brennan lowered the firm’s price target on 10x Genomics (TXG) to $15 from $18 and keeps a Hold rating on the shares. The ...
PLEASANTON, Calif., Feb. 23, 2025 /PRNewswire/ -- At the Advances in Genome Biology and Technology (AGBT) General Meeting, 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results